Cytotoxic Treatment in Patients with Malignant Carcinoid Tumors: Response to streptozocin-alone or in combination with 5-FU
Thirty-one patients with malignant carcinoid tumors were treated with streptozocin-alone (n=7) or in combination with FU (n=24). The responses to treatment were followed by the determination of tumor markers, urinary 5-HIAA, serum PP, HCG-a and -β subunits, as well as determination of the size of li...
Gespeichert in:
| Veröffentlicht in: | Acta oncologica 1987, Vol.26 (6), p.429-432 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 432 |
|---|---|
| container_issue | 6 |
| container_start_page | 429 |
| container_title | Acta oncologica |
| container_volume | 26 |
| creator | Öberg, K. Norheim, I. Lundqvist, G. Wide, L. |
| description | Thirty-one patients with malignant carcinoid tumors were treated with streptozocin-alone (n=7) or in combination with FU (n=24). The responses to treatment were followed by the determination of tumor markers, urinary 5-HIAA, serum PP, HCG-a and -β subunits, as well as determination of the size of liver metastases on computerized tomography or ultrasonography. Three patients (9.7%) showed objective responses with a mean remission time of 2.7 months. Eighteen patients (58%) showed stable disease, whereas ten patients (32.3%) showed progressive disease directly from the start of therapy. A good correlation was found between the changes in tumor markers and tumor size, although the changes occurred earlier in the markers than in the size. Estimated median survival from the time of histologically verified carcinoid tumor was 41 months and from start of therapy 22 months. Our data indicate that combination treatment with streptozocin and 5-fluorouracil is of little value for patients with malignant carcinoid tumors. |
| doi_str_mv | 10.3109/02841868709113712 |
| format | Article |
| fullrecord | <record><control><sourceid>informahealthcare_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_02841868709113712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_02841868709113712</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3352-ed248ed803d22cd91145a673faa01917add5ef82555e0ba8fb9f736f130f711a3</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMotT5-gAshC7ejeTSTGV1J8QWKIhW6G24ziY3MJCVJ8fXnTWlxI7i6F853DvcehI4oOeWU1GeEVSNalZUkNaVcUraFhrQUtGCsnG6j4UovMjDdRXsxvhFCGJdigAZsJKjgZIi-x5_JJ_9hFZ4EDanXLmHr8BMkm9eI322a4wfo7KuDLI0hKOu8bfFk2fsQz_GzjgvvosbJ45iCXiT_5TNTQOedxj6s4pTvZ9blTO_WiaK4fjlAOwa6qA83cx-9XF9NxrfF_ePN3fjyvlCcC1bolo0q3VaEt4ypNn86ElBKbgAIramEthXaVEwIockMKjOrjeSloZwYSSnwfUTXuSr4GIM2zSLYHsJnQ0mz6rH502P2HK89i-Ws1-2vY1Nc1k82OkQFnQnglI2_mMz3ybrO2MUas8740MNcQ5fmCoJu3vwyuPz2P0f8ALXpjnQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cytotoxic Treatment in Patients with Malignant Carcinoid Tumors: Response to streptozocin-alone or in combination with 5-FU</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Öberg, K. ; Norheim, I. ; Lundqvist, G. ; Wide, L.</creator><creatorcontrib>Öberg, K. ; Norheim, I. ; Lundqvist, G. ; Wide, L.</creatorcontrib><description>Thirty-one patients with malignant carcinoid tumors were treated with streptozocin-alone (n=7) or in combination with FU (n=24). The responses to treatment were followed by the determination of tumor markers, urinary 5-HIAA, serum PP, HCG-a and -β subunits, as well as determination of the size of liver metastases on computerized tomography or ultrasonography. Three patients (9.7%) showed objective responses with a mean remission time of 2.7 months. Eighteen patients (58%) showed stable disease, whereas ten patients (32.3%) showed progressive disease directly from the start of therapy. A good correlation was found between the changes in tumor markers and tumor size, although the changes occurred earlier in the markers than in the size. Estimated median survival from the time of histologically verified carcinoid tumor was 41 months and from start of therapy 22 months. Our data indicate that combination treatment with streptozocin and 5-fluorouracil is of little value for patients with malignant carcinoid tumors.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.3109/02841868709113712</identifier><identifier>PMID: 2451530</identifier><identifier>CODEN: ACTOEL</identifier><language>eng</language><publisher>Basingstoke: Informa UK Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoid Tumor - drug therapy ; Carcinoid Tumor - mortality ; Chemotherapy ; Chorionic Gonadotropin - blood ; Female ; Fluorouracil - administration & dosage ; Humans ; Hydroxyindoleacetic Acid - urine ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Streptozocin - administration & dosage ; Streptozocin - therapeutic use</subject><ispartof>Acta oncologica, 1987, Vol.26 (6), p.429-432</ispartof><rights>1987 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1987</rights><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3352-ed248ed803d22cd91145a673faa01917add5ef82555e0ba8fb9f736f130f711a3</citedby><cites>FETCH-LOGICAL-c3352-ed248ed803d22cd91145a673faa01917add5ef82555e0ba8fb9f736f130f711a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/02841868709113712$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/02841868709113712$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,4024,27923,27924,27925,61221,61402</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7673799$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2451530$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Öberg, K.</creatorcontrib><creatorcontrib>Norheim, I.</creatorcontrib><creatorcontrib>Lundqvist, G.</creatorcontrib><creatorcontrib>Wide, L.</creatorcontrib><title>Cytotoxic Treatment in Patients with Malignant Carcinoid Tumors: Response to streptozocin-alone or in combination with 5-FU</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><description>Thirty-one patients with malignant carcinoid tumors were treated with streptozocin-alone (n=7) or in combination with FU (n=24). The responses to treatment were followed by the determination of tumor markers, urinary 5-HIAA, serum PP, HCG-a and -β subunits, as well as determination of the size of liver metastases on computerized tomography or ultrasonography. Three patients (9.7%) showed objective responses with a mean remission time of 2.7 months. Eighteen patients (58%) showed stable disease, whereas ten patients (32.3%) showed progressive disease directly from the start of therapy. A good correlation was found between the changes in tumor markers and tumor size, although the changes occurred earlier in the markers than in the size. Estimated median survival from the time of histologically verified carcinoid tumor was 41 months and from start of therapy 22 months. Our data indicate that combination treatment with streptozocin and 5-fluorouracil is of little value for patients with malignant carcinoid tumors.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoid Tumor - drug therapy</subject><subject>Carcinoid Tumor - mortality</subject><subject>Chemotherapy</subject><subject>Chorionic Gonadotropin - blood</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Humans</subject><subject>Hydroxyindoleacetic Acid - urine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Streptozocin - administration & dosage</subject><subject>Streptozocin - therapeutic use</subject><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLAzEUhYMotT5-gAshC7ejeTSTGV1J8QWKIhW6G24ziY3MJCVJ8fXnTWlxI7i6F853DvcehI4oOeWU1GeEVSNalZUkNaVcUraFhrQUtGCsnG6j4UovMjDdRXsxvhFCGJdigAZsJKjgZIi-x5_JJ_9hFZ4EDanXLmHr8BMkm9eI322a4wfo7KuDLI0hKOu8bfFk2fsQz_GzjgvvosbJ45iCXiT_5TNTQOedxj6s4pTvZ9blTO_WiaK4fjlAOwa6qA83cx-9XF9NxrfF_ePN3fjyvlCcC1bolo0q3VaEt4ypNn86ElBKbgAIramEthXaVEwIockMKjOrjeSloZwYSSnwfUTXuSr4GIM2zSLYHsJnQ0mz6rH502P2HK89i-Ws1-2vY1Nc1k82OkQFnQnglI2_mMz3ybrO2MUas8740MNcQ5fmCoJu3vwyuPz2P0f8ALXpjnQ</recordid><startdate>1987</startdate><enddate>1987</enddate><creator>Öberg, K.</creator><creator>Norheim, I.</creator><creator>Lundqvist, G.</creator><creator>Wide, L.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1987</creationdate><title>Cytotoxic Treatment in Patients with Malignant Carcinoid Tumors: Response to streptozocin-alone or in combination with 5-FU</title><author>Öberg, K. ; Norheim, I. ; Lundqvist, G. ; Wide, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3352-ed248ed803d22cd91145a673faa01917add5ef82555e0ba8fb9f736f130f711a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoid Tumor - drug therapy</topic><topic>Carcinoid Tumor - mortality</topic><topic>Chemotherapy</topic><topic>Chorionic Gonadotropin - blood</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Humans</topic><topic>Hydroxyindoleacetic Acid - urine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Streptozocin - administration & dosage</topic><topic>Streptozocin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Öberg, K.</creatorcontrib><creatorcontrib>Norheim, I.</creatorcontrib><creatorcontrib>Lundqvist, G.</creatorcontrib><creatorcontrib>Wide, L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Öberg, K.</au><au>Norheim, I.</au><au>Lundqvist, G.</au><au>Wide, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytotoxic Treatment in Patients with Malignant Carcinoid Tumors: Response to streptozocin-alone or in combination with 5-FU</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>1987</date><risdate>1987</risdate><volume>26</volume><issue>6</issue><spage>429</spage><epage>432</epage><pages>429-432</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><coden>ACTOEL</coden><abstract>Thirty-one patients with malignant carcinoid tumors were treated with streptozocin-alone (n=7) or in combination with FU (n=24). The responses to treatment were followed by the determination of tumor markers, urinary 5-HIAA, serum PP, HCG-a and -β subunits, as well as determination of the size of liver metastases on computerized tomography or ultrasonography. Three patients (9.7%) showed objective responses with a mean remission time of 2.7 months. Eighteen patients (58%) showed stable disease, whereas ten patients (32.3%) showed progressive disease directly from the start of therapy. A good correlation was found between the changes in tumor markers and tumor size, although the changes occurred earlier in the markers than in the size. Estimated median survival from the time of histologically verified carcinoid tumor was 41 months and from start of therapy 22 months. Our data indicate that combination treatment with streptozocin and 5-fluorouracil is of little value for patients with malignant carcinoid tumors.</abstract><cop>Basingstoke</cop><pub>Informa UK Ltd</pub><pmid>2451530</pmid><doi>10.3109/02841868709113712</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0284-186X |
| ispartof | Acta oncologica, 1987, Vol.26 (6), p.429-432 |
| issn | 0284-186X 1651-226X |
| language | eng |
| recordid | cdi_crossref_primary_10_3109_02841868709113712 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles); EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoid Tumor - drug therapy Carcinoid Tumor - mortality Chemotherapy Chorionic Gonadotropin - blood Female Fluorouracil - administration & dosage Humans Hydroxyindoleacetic Acid - urine Male Medical sciences Middle Aged Pharmacology. Drug treatments Streptozocin - administration & dosage Streptozocin - therapeutic use |
| title | Cytotoxic Treatment in Patients with Malignant Carcinoid Tumors: Response to streptozocin-alone or in combination with 5-FU |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T00%3A14%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytotoxic%20Treatment%20in%20Patients%20with%20Malignant%20Carcinoid%20Tumors:%20Response%20to%20streptozocin-alone%20or%20in%20combination%20with%205-FU&rft.jtitle=Acta%20oncologica&rft.au=%C3%96berg,%20K.&rft.date=1987&rft.volume=26&rft.issue=6&rft.spage=429&rft.epage=432&rft.pages=429-432&rft.issn=0284-186X&rft.eissn=1651-226X&rft.coden=ACTOEL&rft_id=info:doi/10.3109/02841868709113712&rft_dat=%3Cinformahealthcare_cross%3E10_3109_02841868709113712%3C/informahealthcare_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2451530&rfr_iscdi=true |